Bronstein, Gewirtz & Grossman LLC Urges Erasca, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

A class action lawsuit has been filed against Erasca, Inc. alleging that the company made false and misleading statements regarding ERAS-0015's preclinical data, which was based on improper comparisons to Revolution Medicines and placed the company at risk of patent and trade secret violations. Investors who purchased Erasca securities between January 14, 2025 and April 26, 2026 are encouraged to join the case, with a lead plaintiff deadline of August 10, 2026.

06/23/2026, 12:00 PM • GlobeNewswire

Deadline Alert: Erasca, Inc. (ERAS) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit

Erasca, Inc. faces a securities fraud class action lawsuit after disclosing a patent infringement allegation from Revolution Medicines on April 27, 2026, followed by a patient death in its ERAS-0015 Phase 1 trial on April 28, 2026. The stock plummeted 48.3% on April 28 after the death disclosure. The lawsuit alleges the company made materially false statements about ERAS-0015's preclinical data and failed to disclose material risks. The deadline to file a lead plaintiff motion is August 10, 2026.

06/22/2026, 12:57 PM • GlobeNewswire

ROSEN, LEADING INVESTOR COUNSEL, Encourages Erasca, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ERAS

Rosen Law Firm is reminding investors who purchased Erasca, Inc. common stock between January 14, 2025 and April 26, 2026 of the August 10, 2026 lead plaintiff deadline in an ongoing securities class action. The lawsuit alleges that Erasca and its executives made false and misleading statements about its lead oncology drug candidate ERAS-0015, including improper comparisons to a competing drug and undisclosed patent disputes.

06/21/2026, 6:35 AM • GlobeNewswire

ERAS INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Erasca, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Erasca, Inc. faces a securities class action lawsuit alleging that the company and its executives made false statements about its lead drug candidate ERAS-0015. The lawsuit claims preclinical data was based on improper comparisons and lacked reasonable basis. On April 27, 2026, Erasca disclosed a patent infringement assertion from Revolution Medicines and reported a patient death in Phase I trials, causing the stock to plummet nearly 59% over two trading days. Investors with substantial losses can seek appointment as lead plaintiff by August 10, 2026.

06/20/2026, 11:30 AM • GlobeNewswire

ERAS UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Erasca (ERAS) Investors of Securities Class Action Lawsuit Deadline on August 10, 2026

Faruqi & Faruqi, LLP is investigating securities fraud claims against Erasca, Inc. (NASDAQ: ERAS) for allegedly making false statements about its ERAS-0015 drug candidate based on improper comparisons to Revolution Medicines' compound. The company disclosed patent infringement allegations and a patient death in Phase 1 trials on April 27, 2026, causing the stock to plummet from $21.49 to $9.90 per share over two trading days. The deadline to seek lead plaintiff status is August 10, 2026.

06/20/2026, 8:40 AM • GlobeNewswire

CALIX DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Calix, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - CALX

Rosen Law Firm is notifying investors in Calix, Inc., Erasca, Inc., and Graphic Packaging Holding Company of ongoing securities class action lawsuits. The firm is seeking lead plaintiffs with a July 27, 2026 deadline. Calix investors are accused of making false statements regarding profit margins related to memory component purchasing, while the firm encourages investors with losses exceeding $100,000 to seek legal counsel.

06/18/2026, 10:25 PM • GlobeNewswire

ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Erasca, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ERAS

Rosen Law Firm is reminding investors who purchased Erasca, Inc. (NASDAQ: ERAS) stock between January 14, 2025 and April 26, 2026 of an August 10, 2026 deadline to join a securities class action lawsuit. The lawsuit alleges that Erasca and its executives made false and misleading statements about its lead oncology drug candidate ERAS-0015, including improper comparisons to a competing drug that lacked reasonable basis and exposed the company to patent disputes.

06/18/2026, 7:22 PM • GlobeNewswire

Erasca, Inc. (ERAS) Faces Securities Class Action Amid Patient Death, Intellectual Property Questions, $2.8 Billion Market Cap Loss -- HBSS

Erasca, Inc. (NASDAQ: ERAS) stock plummeted 48% ($9.25) after the company disclosed a patient death following ERAS-0015 treatment and faced patent infringement accusations from Revolution Medicines. The company allegedly misled investors about the drug's efficacy and intellectual property protection. The disclosures wiped out $2.8 billion in market capitalization, prompting a securities class action lawsuit covering the period from January 14, 2025 to April 26, 2026.

06/18/2026, 1:43 PM • GlobeNewswire

DEADLINE ALERT for BTGO, ERAS, NNOX, and MSFT: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

Class action lawsuits have been filed against BitGo Holdings, Erasca, Nano-X Imaging, and Microsoft Corporation, alleging that defendants made materially false and misleading statements and failed to disclose material adverse facts about their businesses. Investors have until August 7-11, 2026 to file lead plaintiff motions.

06/18/2026, 12:53 PM • GlobeNewswire

(NASDAQ:ERAS) ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Erasca, Inc. and Encourages Investors to Contact the Firm

A class action lawsuit has been filed against Erasca, Inc. (NASDAQ: ERAS) alleging that the company made false and misleading statements regarding its ERAS-0015 drug candidate. The lawsuit claims the preclinical data was based on improper comparisons and lacked reasonable basis. On April 28, 2026, Erasca disclosed a patent infringement letter from Revolution Medicines, causing the stock to plummet 48% from $19.15 to $9.90 per share.

06/17/2026, 7:08 PM • GlobeNewswire

ROSEN, TOP-RANKED INVESTOR COUNSEL, Encourages Erasca, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ERAS

Rosen Law Firm has filed a class action lawsuit against Erasca, Inc. on behalf of investors who purchased common stock between January 14, 2025 and April 26, 2026. The lawsuit alleges that Erasca and its executives made false and misleading statements about its lead oncology drug candidate ERAS-0015, including improper comparisons to a competing drug and undisclosed patent disputes. Investors who wish to serve as lead plaintiff must file by August 10, 2026.

06/15/2026, 10:38 PM • GlobeNewswire

Erasca, Inc. (ERAS) Faces Securities Class Action Amid Patient Death, Intellectual Property Questions, $2.8 Billion Market Cap Loss -- HBSS

Erasca, Inc. (NASDAQ: ERAS) stock plummeted 48% ($9.25) after the company disclosed a patient death following ERAS-0015 treatment and faced patent infringement accusations from Revolution Medicines. The company allegedly misled investors about the drug's efficacy comparisons and intellectual property protection. The disclosures wiped out $2.8 billion in market capitalization, prompting a securities class action lawsuit covering the period from January 14, 2025 to April 26, 2026.

06/15/2026, 8:51 PM • GlobeNewswire

ROSEN, LEADING INVESTOR RIGHTS COUNSEL, Encourages Verra Mobility Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action - VRRM

Rosen Law Firm has filed class action lawsuits against Verra Mobility Corporation, Erasca, Inc., and FS KKR Capital Corp. on behalf of investors who suffered losses. The Verra Mobility lawsuit alleges the company made false statements regarding its relationship with Avis Budget Group and concealed material adverse facts. Investors have until August 4, 2026 to move the court to serve as lead plaintiff.

06/12/2026, 1:50 PM • GlobeNewswire

Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Erasca, Inc. and Encourages Investors to Contact the Firm

A class action lawsuit has been filed against Erasca, Inc. alleging that the company made false and misleading statements regarding its ERAS-0015 drug candidate. The lawsuit stems from a patent infringement letter received from Revolution Medicines on April 28, 2026, which triggered a 48% stock price decline from $19.15 to $9.90 per share. Investors who purchased Erasca stock between January 14, 2025 and April 26, 2026 are encouraged to contact the law firm.

06/11/2026, 5:54 PM • GlobeNewswire

ADMA LAWSUIT: ADMA Biologics, Inc. Sued For Securities Fraud; Investors Should Contact Block & Leviton to Possibly Recover Losses

ADMA Biologics has been sued for securities fraud for allegedly misleading investors about revenue growth through a channel-stuffing scheme involving its ASCENIV product and failing to disclose a related-party distribution relationship. A Culper Research report revealed the growth was driven by excess inventory rather than genuine demand, causing the stock to plummet from $13.59 to $8.29 per share. Investors who purchased shares between August 9, 2024, and March 25, 2026, may be eligible to recover losses.

06/10/2026, 8:17 PM • GlobeNewswire